“Carcinoma de pulmón célula no pequeña: ¿hay diferencias por histología utilizando inmunoterapia?” - page 6

NSCLC development
Pretreated advanced 1st-line advanced Adjuvant
Unresectable
Stage IIIa/b
Nivolumab Fully human IgG4 mAb BMS
Pembrolizumab Humanized IgG4 mAb Merk
Pidilizumab Humanized IgG1 mAb CureTech
PDR001 Humanized IgG4 mAb Novartis
AMP-224 Recombinant PD-L2-Fc
fusion prot GSK
MEDI-0680 Humanized IgG4 mAb Medimmune/AZ
REGN2810 Humanized IgG4 mAb Regeneron/Sano
fi
Durvalumab Engineered human IgG1
mAb Medimmune/AZ
Atezolizumab Engineered human IgG1
mAb Roche
Avelumab Engineered human IgG1
mAb EMD Serono
BMS936559 Fully human IgG4 mAb BMS
Ipilimumab Human anti-CTLA4
monoclonal IgG4 BMS
Tremelimumab Fully human monoclonal
anti-CTLA4 IgG2 AZ
reported
On going
Introduction